BioSpace News Archive

Valneva SE, a specialty vaccine company, announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001.

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Karen Massey will join argenx as Chief Operating Officer, effective March 13, 2023.

Oxurion NV announced that it has entered into a Subscription Agreement for Convertible Bonds with Atlas Special Opportunities, LLC, providing for up to €20 million in financing.

Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced financial results for the 12-month period from January 1 to December 31, 2022 and provided a corporate update.

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company’s rising ambition on serving and collaborating with world’s best biotech start-ups and ventures.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and is used in the treatment of a known or suspected opioid overdose emergency.

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the 43rd Annual TD Cowen Health Care Conference on Wednesday, March 8 at 10:30 am ET ( 7:30 am PT / 3:30 pm GMT ).

Immunic, Inc. today announced participation in the following investor and scientific conferences in March.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 110,400 shares, and restricted stock units (RSUs) covering an aggregate of 51,300 shares, of BioCryst common stock.

Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).